Health

Anti-CD38-Based Quadruplet Improves Outcomes in Transplant-Ineligible Myeloma

TribeNews
By TribeNews 5 Views Add a Comment
0 Min Read
Anti-CD38-Based Quadruplet Improves Outcomes in Transplant-Ineligible Myeloma

MedPage Today) — Daratumumab (Darzalex) plus the standard triplet of bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (D-VRd) significantly improved clinical outcomes versus VRd alone in patients with transplant-ineligible or…

Leave a Comment
Ads Blocker Image Powered by Code Help Pro

Ads Blocker Detected & This Is Prohibited!!!

We have detected that you are using extensions to block ads and you are also not using our official app. Your Account Have been Flagged and reported, pending de-activation & All your earning will be wiped out. Please turn off the software to continue

You cannot copy content of this app